Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Outperform Rating from Analysts at Wolfe Research

Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note issued to investors on Friday, Marketbeat.com reports. The brokerage issued an outperform rating and a $1,150.00 price target on the biopharmaceutical company’s stock.

A number of other analysts also recently issued reports on the stock. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Morgan Stanley cut their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Wells Fargo & Company cut their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, October 22nd. Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Finally, TD Cowen boosted their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $1,099.55.

Regeneron Pharmaceuticals Trading Down 3.3 %

Shares of Regeneron Pharmaceuticals stock opened at $756.81 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock has a market cap of $83.17 billion, a PE ratio of 18.73, a PEG ratio of 2.86 and a beta of 0.15. Regeneron Pharmaceuticals has a 52-week low of $753.69 and a 52-week high of $1,211.20. The firm has a 50-day moving average of $985.21 and a 200-day moving average of $1,034.89.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This represents a 27.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.48% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rakuten Securities Inc. increased its position in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares during the period. Stephens Consulting LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $26,000. Sachetta LLC increased its position in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares during the period. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth $26,000. Finally, Crewe Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $28,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.